HPV-positive oropharyngeal cancer: the decisions you may face
7 treatment settings, 4 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Diagnosis and staging
Fine-needle biopsy of the neck node with p16 staining, HPV confirmation where p16 is equivocal, examination and imaging of the tonsils and tongue base, and PET-CT; staged with the HPV-positive system.
PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.
- Anatomy plus biology
- Standard for lymphoma, lung, melanoma, head and neck staging
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- CT radiation added to PET dose
- Is PET/CT the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (diagnosis and staging), which of the standard options do you recommend and why?Why: Guideline options include: Fine-needle biopsy of the neck node with p16 staining, HPV confirmation where p16 is equivocal, examination and imaging of the tonsils and tongue base, and PET-CT; staged with the HPV-positive system.
Add these to your appointment list, or take the full question set for this cancer.
Early disease (small primary, limited nodes)
Transoral robotic surgery with neck dissection and pathology-guided adjuvant radiotherapy (E3311), or radiotherapy alone; choice by expected swallowing and voice.
Transoral robotic surgery removes early (T1 to T2) throat tumours through the mouth with a robot and 3D endoscope, avoiding splitting the jaw or a tracheostomy. In HPV-positive oropharyngeal cancer the pathology then guides how much radiation to add, but randomised trials found it no better than radiation for swallowing, and surgeon volume matters.
- Avoids mandibulotomy and tracheostomy
- Pathology-based selection of adjuvant therapy
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
- Conformal dose, fewer side effects
- Hypofractionation saves visits
- Resectable HPV-positive oropharyngeal cancer: transoral surgery and neck dissection, then adjuvant treatment by pathological risk, with intermediate-risk patients randomised to 50 or 60 Gy of radiotherapy
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Two-year progression-free survival 96.9% (observation), 94.9% (50 Gy), 96.0% (60 Gy) and 90.7% (high-risk chemoradiation).
Progression-free survival at 2 years (%): Low risk, observation 96.9 vs Intermediate risk, 50 Gy 94.9 vs Intermediate risk, 60 Gy 96 vs High risk, 66 Gy + cisplatin 90.7
- Bleeding risk, swallowing morbidity
- Not superior to radiation in randomised comparison for function
- Low-dose bath to normal tissue
- Motion management
- Between Transoral robotic surgery (TORS) and IMRT / IGRT (modern external beam), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in ECOG-ACRIN E3311, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (early disease (small primary, limited nodes)), which of the standard options do you recommend and why?Why: Guideline options include: Transoral robotic surgery with neck dissection and pathology-guided adjuvant radiotherapy (E3311), or radiotherapy alone; choice by expected swallowing and voice.
- How do the results of ECOG-ACRIN E3311 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Locally advanced disease
Cisplatin chemoradiation to 70 Gy; cetuximab only for patients who cannot have cisplatin, since RTOG 1016 and De-ESCALaTE showed it inferior.
Cisplatin is the original platinum chemotherapy, discovered by accident in 1965; it cures testicular cancer and makes radiation work better in cervical and head and neck cancer.
IMRT and IGRT shape the radiation beam to the tumour's outline from multiple angles and check the patient's position with a scan before every session, so surrounding organs receive less dose. Fewer, larger doses are now standard in breast and prostate cancer, but a low-dose bath still spreads across normal tissue.
- Conformal dose, fewer side effects
- Hypofractionation saves visits
Cetuximab is a chimeric antibody that blocks the EGFR growth receptor. It is used with FOLFIRI or FOLFOX in RAS wild-type, left-sided bowel cancer, with encorafenib in BRAF V600E disease, with KRAS G12C inhibitors, and with radiation or chemotherapy in head and neck cancer; RAS-mutant tumours gain nothing and may be harmed, so RAS testing comes first.
- HPV-positive oropharyngeal cancer: radiotherapy with cetuximab versus radiotherapy with cisplatin
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- 5-year overall survival 84.6% (cisplatin) vs 77.9% (cetuximab); non-inferiority not met.
Overall survival at 5 years (%): Radiotherapy plus cisplatin 84.6 (n=406) vs Radiotherapy plus cetuximab 77.9 (n=399) - Low-risk HPV-positive oropharyngeal cancer: radiotherapy with cetuximab versus radiotherapy with cisplatin
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- Severe toxicity similar; 2-year overall survival 97.5% (cisplatin) vs 89.4% (cetuximab).
Severe (grade 3-5) toxicity events per patient at 24 months (events per patient): Radiotherapy + cisplatin 4.8 (n=166) vs Radiotherapy + cetuximab 4.8 (n=168) · source
- Dose reduce or avoid for CrCl below 60 (carboplatin is the alternative).
- Low-dose bath to normal tissue
- Motion management
- Between Cisplatin, IMRT / IGRT (modern external beam) and Cetuximab, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in RTOG 1016 and De-ESCALaTE HPV, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (locally advanced disease), which of the standard options do you recommend and why?Why: Guideline options include: Cisplatin chemoradiation to 70 Gy; cetuximab only for patients who cannot have cisplatin, since RTOG 1016 and De-ESCALaTE showed it inferior.
- Am I a candidate for Cisplatin, Cetuximab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of RTOG 1016 and De-ESCALaTE HPV apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
De-escalation
Reduced-dose or chemotherapy-free treatment only within a trial; NRG-HN005 showed that lowering the dose in definitive chemoradiation on HPV status alone loses control.
A blood test that detects fragments of the virus DNA shed by HPV-positive throat cancers, to confirm diagnosis, track response, and catch recurrence early.
- Highly specific to the tumour
- Cheap, repeatable, earlier than imaging
- Low-risk HPV-positive oropharyngeal cancer: reduced-dose radiation (60 Gy) with or without cisplatin, or with nivolumab, vs standard 70 Gy chemoradiation
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- HN005: de-escalated arms had worse PFS; control 2-year PFS 98%.
HN005: progression-free survival at 2 years (phase II non-inferiority) (%): 70 Gy + cisplatin (standard) 98.1 (n=136) vs 60 Gy + cisplatin 88.6 (n=116) vs 60 Gy + nivolumab 90.3 (n=132) · source - Resectable HPV-positive oropharyngeal cancer: transoral surgery and neck dissection, then risk-stratified reduction of adjuvant treatment (50 versus 60 Gy in intermediate risk; radiotherapy alone versus chemoradiation in high risk), with swallowing function and survival as endpoints
No headline result recorded yet.
- Only for HPV-driven disease
- Interventional trials proving benefit of acting on it are ongoing
- Is Circulating tumour HPV DNA (ctHPV-DNA) the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in NRG-HN002 & NRG-HN005 (HPV+ de-escalation) and PATHOS, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (de-escalation), which of the standard options do you recommend and why?Why: Guideline options include: Reduced-dose or chemotherapy-free treatment only within a trial; NRG-HN005 showed that lowering the dose in definitive chemoradiation on HPV status alone loses control.
- How do the results of NRG-HN002 & NRG-HN005 (HPV+ de-escalation) and PATHOS apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Surveillance
Examination and PET-CT at about three months; circulating tumour HPV DNA is emerging as a blood test for recurrence.
PET and CT in one machine, so hot spots on the PET are pinned to exact locations on the CT.
- Anatomy plus biology
- Standard for lymphoma, lung, melanoma, head and neck staging
A blood test that detects fragments of the virus DNA shed by HPV-positive throat cancers, to confirm diagnosis, track response, and catch recurrence early.
- Highly specific to the tumour
- Cheap, repeatable, earlier than imaging
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- CT radiation added to PET dose
- Only for HPV-driven disease
- Interventional trials proving benefit of acting on it are ongoing
- Between PET/CT and Circulating tumour HPV DNA (ctHPV-DNA), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (surveillance), which of the standard options do you recommend and why?Why: Guideline options include: Examination and PET-CT at about three months; circulating tumour HPV DNA is emerging as a blood test for recurrence.
Add these to your appointment list, or take the full question set for this cancer.
Recurrent or metastatic
Pembrolizumab alone or with platinum-fluorouracil (KEYNOTE-048); HPV-positive tumours respond at least as well as HPV-negative ones.
Pembrolizumab is a PD-1 blocking antibody approved in more than 40 settings, from melanoma and lung cancer to the first tumour-agnostic approval for mismatch-repair-deficient tumours in 2017, and before and after surgery in triple-negative breast cancer. A subcutaneous form arrived in 2025, and it is the backbone partner for ADCs and personalised neoantigen vaccines.
- Tests PembrolizumabUntreated recurrent or metastatic HNSCC: pembrolizumab alone, pembrolizumab + platinum/5-FU, or cetuximab + platinum/5-FU (EXTREME)
OS 14.9 vs 10.7 months (CPS ≥20, monotherapy); 13.0 vs 10.7 (all, with chemotherapy).
Overall survival, CPS ≥20, pembrolizumab monotherapy (months): Pembrolizumab 14.9 vs Cetuximab + chemotherapy 10.7 · HR 0.61 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Hypothyroidism (immune-mediated) · Pooled monotherapy data, >2,800 patients | 8% | - |
| Pneumonitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 3.4% | - |
| Colitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 1.7% | - |
| Hepatitis (immune-mediated) · Pooled monotherapy data, >2,800 patients | 0.7% | - |
- No pharmacokinetic interactions expected (antibody). See the irAE guide for toxicity management.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Is Pembrolizumab the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?Why: A single standard does not mean a single choice; timing and trials are decisions too.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in KEYNOTE-048, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Pembrolizumab are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- Does your recommendation follow the current guideline (NCCN Guidelines: Head and Neck Cancers), and if it departs from it, why?Why: Departures from guidelines are sometimes right for an individual; they should be explained.
- For my situation (recurrent or metastatic), which of the standard options do you recommend and why?Why: Guideline options include: Pembrolizumab alone or with platinum-fluorouracil (KEYNOTE-048); HPV-positive tumours respond at least as well as HPV-negative ones.
- Am I a candidate for Pembrolizumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of KEYNOTE-048 apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Prevention
HPV vaccination of girls and boys before exposure; catch-up vaccination of men is being argued for.
Vaccines that prevent the viral infections behind cervical, throat, anal, and liver cancers. The most effective anti-cancer intervention ever created.
- Prevents cancer outright
- Cheap at scale
A vaccine against nine HPV types that prevents about 90% of cervical cancers, and now works with a single dose.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- Coverage gaps, vaccine hesitancy
- Between HPV & HBV vaccination and Nonavalent HPV vaccine, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (prevention), which of the standard options do you recommend and why?Why: Guideline options include: HPV vaccination of girls and boys before exposure; catch-up vaccination of men is being argued for.
- Am I a candidate for Nonavalent HPV vaccine, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.